Results 161 to 170 of about 4,368 (201)

Finerenon

pharma-kritik, 2022
Als erster nicht-steroidaler Mineralokortikoid-Rezeptorantagonist (MRA) beeinflusst Finerenon (Kerendia®) die Nierenfunktion bei Personen mit einem Typ-2-Diabetes und Niereninsuffizienz vorteilhaft. Weitere Untersuchungen müssen zeigen, ob mit der neuen Substanz mehr als z.B. mit Eplerenon (Inspra® u.a.) erreicht wird.
openaire   +1 more source

Finerenone (Kerendia)

Canadian Journal of Health Technologies, 2023
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire   +1 more source

Patient Counseling for Finerenone

Indian Journal Of Clinical Practice, 2023
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist, which is used to retard the progression of chronic kidney disease in persons with type 2 diabetes. This communication describes the various aspects of patient counseling needed to ensure safe and effective usage of the molecule.
null Sanjay Kalra, null Banshi Saboo, null Beatrice Anne, null Mathew John, null Pradip Dalwadi, null Shehla Shaikh   +5 more
openaire   +1 more source

Finerenone for Albuminuria in Patients With Diabetic Nephropathy

JAMA, 2016
To the Editor Dr Bakris and colleagues1 evaluated the safety and efficacy of dual blockade of the renin-angiotensin-aldosterone system by adding the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker in patients with diabetic nephropathy. The authors
Yanhuan, Feng, Xiaoxi, Zeng, Ping, Fu
openaire   +2 more sources

Finerenone (Kerendia)

Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire   +1 more source

Finerenone

Reactions Weekly
  +5 more sources

Finerenon bei Herzinsuffizienz

pharma-kritik
Finerenon ist neu auch bei Personen zugelassen, die an einer Herzinsuffizienz mit erhaltener oder nur leicht eingeschränkter linksventrikulärer Auswurffraktion erkrankt sind. Der deutsche «Arzneimittelbrief» hat den möglichen Zusatznutzen beurteilt.
openaire   +1 more source

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes

Circulation, 2021
Bertram Pitt, Luis Miguel Ruilope, Rajiv Agarwal   +2 more
exaly  

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Diabetes Care, 2022
Qinkai Chen, Shigehiro Katayama, Heinz Drexel   +2 more
exaly  

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Diabetes Care, 2022
Bertram Pitt, Qinkai Chen, Richard J MacIsaac   +2 more
exaly